Supernus Pharmaceuticals reported its third-quarter results, exceeding Wall Street’s revenue and profit expectations, yet the market reacted negatively, largely due to concerns regarding execution challenges and the company’s forward-looking guidance. Management attributed the quarter’s growth to robust demand for Qelbree and GOCOVRI, along with initial contributions from Onapgo and revenue generated through collaborations with Biogen regarding Zurzuvae. CEO Jack Khattar acknowledged that supply constraints surrounding Onapgo represented a “high-quality problem” – one that necessitated urgent resolution – despite limiting the company’s ability to fully meet patient demand. Furthermore, management cited increased operating expenses stemming from the recent Sage acquisition as a primary factor contributing to the reduced profitability. The market’s reaction underscores the complexities surrounding Supernus’ strategy and the operational hurdles impacting its growth trajectory.
The company’s third-quarter 2025 financial results highlighted key performance indicators. Revenue totaled $192.1 million, representing a 9.3% year-over-year increase and a 5.5% beat against analyst estimates. Adjusted earnings per share (EPS) reached $0.61, a 25.9% miss compared to anticipated figures of $0.82. Adjusted EBITDA amounted to $66.71 million, a significantly stronger performance than the projected $20 million, with a margin of 34.7%. These figures demonstrate Supernus’ core product performance but also expose vulnerabilities related to supply chain management and overall operational efficiency. The company’s revenue guidance for the full fiscal year was raised to $695 million at the midpoint, an upward revision from the prior projection of $685 million, signaling confidence in sustained sales growth. Operating Margin, however, decreased to -31.4% compared to 23.2% in the same quarter of the previous year, reflecting the ongoing impact of strategic investments and supply chain disruptions. The market capitalization stands at $2.60 billion.
The company’s leadership’s commentary and analyst questioning sessions offered further insights into the business. Analyst Lin Tsai (Jefferies LLC) inquired about the potential number of additional patients who could have initiated treatment with Onapgo if supply constraints hadn’t been a factor. CEO Jack Khattar responded with a difficult-to-quantify estimate but reiterated the company’s strong demand and commitment to rapidly resolving these bottlenecks. Stacy Ku (TD Cowen) pressed for specific details regarding the timeline for resolving Onapgo’s supply issues. Khattar described capacity limitations as the primary constraint and stated that efforts were presently focused on cartridge production. He refrained from providing a definite resolution date. David Amsellem (Piper Sandler) questioned the potential erosion of patient market share to competitors due to Onapgo shortages and explored Supernus’ willingness to acquire full ownership of the Biogen-Zurzuvae partnership. Khattar emphasized the company’s dedication to long-term patient retention and openness to expanding the partnership. Pavan Patel (BofA Securities) sought clarity on Onapgo’s projected gross-to-net pricing trajectory and the types of business development assets the company was prioritizing following the Sage acquisition. Khattar indicated that pricing was still stabilizing and reiterated interest in both central nervous system (CNS) and women’s health opportunities. Annabel Samimy (Stifel) asked about physician feedback on Onapgo and the strategies being employed to maintain patient retention during the ongoing supply disruptions. Khattar highlighted positive clinical feedback, particularly among patients switching from Apokyn, and underscored the importance of service quality as a key factor in patient retention.
Looking ahead, the StockStory team will closely monitor key developments. These include (1) progress in resolving Onapgo’s supply chain bottleneck and its resulting impact on patient retention, (2) the pace of integration and realized synergies from the Sage acquisition, and (3) continued prescription growth for Qelbree and GOCOVRI. Significant milestones in pipeline programs and potential business development activity, particularly in the areas of rare CNS disorders or women’s health, will also be closely observed. Supernus Pharmaceuticals currently trades at $44.71, a decrease from $57.08 prior to the earnings release.
The StockStory team will continue to track key trends and catalysts. This includes monitoring (1) progress in resolving Onapgo’s supply chain bottleneck and its resulting impact on patient retention, (2) the pace of integration and realized synergies from the Sage acquisition, and (3) continued prescription growth for Qelbree and GOCOVRI. Advancements in pipeline programs and potential business development activity, particularly in the areas of rare CNS disorders or women’s health, will also be important milestones. The upcoming quarters will be pivotal for Supernus as it navigates these challenges and capitalizes on its established product portfolio.
